期刊
MOVEMENT DISORDERS
卷 24, 期 15, 页码 2203-2210出版社
WILEY
DOI: 10.1002/mds.22594
关键词
Parkinson's disease; dementia; cerebrospinal fluid; tau; beta-amyloid; neuropsychological function
资金
- Fundacio la Marato de TV3 2006 [N-2006-TV060510]
- Spanish Neurology Society (SEN)
- Spanish Ministry of Education and Science [AP2005-0191]
- Anesthesiology Service
- Knee Surgery Unit
- Movement Disorders Unit research nurse
- Laboratory of Experimental Neurology
Alzheimer's disease (AD)-pathology may play a role in Parkinson's disease (PD)-related dementia (PDD). The aim of this study was to assess cerebrospinal fluid (CSF) levels of tau, phospho-tau, and beta-amyloid, proposed AD biomarkers, and their relationship with cognitive function in PD. Forty PD patients [20 nondemented (PDND); 20 PDD] and 30 controls underwent CSF tau, phospho-tau, and beta-amyloid analysis using specific ELISA techniques. All PD patients and 15 controls underwent neuropsychological testing of fronto-subcortical (attention, fluency) and neocortical (memory, naming, visuoperceptive) functions. CSF markers levels were compared between groups, and compared and correlated with neuropsychological measures in PDND and PDD separately and as a continuum (PD). CSF tau and phospho-tau were higher in PDD than in PDND and controls (P < 0.05). CSF beta-amyloid ranged from high (controls) to intermediate (PDND) and low (PDD) levels (P < 0.001). In all PD and PDD patients, high CSF tau and phospho-tau were associated with impaired memory and naming. In PDND, CSF beta-amyloid was related with phonetic fluency. These findings suggest underlying AD-pathology in PDD in association with cortical cognitive dysfunction, and that low CSF beta-amyloid in PDND patients with impaired phonetic fluency call constitute ail early marker of cognitive dysfunction. (C) 2009 Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据